000288743 001__ 288743
000288743 005__ 20241127134455.0
000288743 0247_ $$2doi$$a10.1007/s11523-024-01044-1
000288743 0247_ $$2pmid$$apmid:38416377
000288743 0247_ $$2ISSN$$a1776-2596
000288743 0247_ $$2ISSN$$a1776-260X
000288743 0247_ $$2altmetric$$aaltmetric:160689804
000288743 037__ $$aDKFZ-2024-00446
000288743 041__ $$aEnglish
000288743 082__ $$a610
000288743 1001_ $$aOlkus, Alexander$$b0
000288743 245__ $$aDurvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data.
000288743 260__ $$aParis$$bSpringer Verlag France S.A.R.L.$$c2024
000288743 3367_ $$2DRIVER$$aarticle
000288743 3367_ $$2DataCite$$aOutput Types/Journal article
000288743 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1712309628_10719
000288743 3367_ $$2BibTeX$$aARTICLE
000288743 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000288743 3367_ $$00$$2EndNote$$aJournal Article
000288743 500__ $$a#LA:F240# / 2024 Mar;19(2):213-221 /NEU/ #LA:D500#
000288743 520__ $$aThe combination of gemcitabine and cisplatin (gem/cis) with the anti-PD-L1-antibody durvalumab was recently approved as first line therapy for biliary tract cancer (BTC) based on the results of the TOPAZ-1 trial.We aim to analyse the feasibility and efficacy of the triple combination therapy in patients with BTC in a real-world setting and in correspondence with the genetic alterations of the cancer.In this single-centre retrospective analysis, all patients with BTC and treated with durvalumab plus gem/cis from April 2022 to September 2023 were included. Survival and treatment response were investigated, within the context of the inclusion and exclusion criteria of TOPAZ-1 and in correspondence with genetic alterations of the cancer.In total, 35 patients, of which 51% met the inclusion criteria of the TOPAZ-1 trial, were analysed. Patients treated within TOPAZ-1 criteria did not have a significantly different median overall survival and progression free survival than the rest of the patients (10.3 versus 9.7 months and 5.3 versus 5 months, respectively). The disease control rate of patients within the TOPAZ-1 criteria was 61.1%, in comparison to 58.8% in the rest of patients. A total of 51 grade 3 and 4 adverse events were observed without significant differences in the subgroups. No specific correlating patterns of genetic alterations with survival and response were observed.The treatment of advanced patients with BTC with durvalumab and gem/cis, even beyond the inclusion criteria of the TOPAZ-1 trial, shows promising safety.
000288743 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000288743 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000288743 7001_ $$aTomczak, Aurelie$$b1
000288743 7001_ $$aBerger, Anne Katrin$$b2
000288743 7001_ $$aRauber, Conrad$$b3
000288743 7001_ $$aPuchas, Philip$$b4
000288743 7001_ $$aWehling, Cyrill$$b5
000288743 7001_ $$aLongerich, Thomas$$b6
000288743 7001_ $$aMehrabi, Arianeb$$b7
000288743 7001_ $$aChang, De-Hua$$b8
000288743 7001_ $$aLiermann, Jakob$$b9
000288743 7001_ $$aSchäfer, Sophia$$b10
000288743 7001_ $$aPfeiffenberger, Jan$$b11
000288743 7001_ $$0P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aJäger, Dirk$$b12$$udkfz
000288743 7001_ $$aMichl, Patrick$$b13
000288743 7001_ $$aSpringfeld, Christoph$$b14
000288743 7001_ $$0P:(DE-He78)54a6641a6c26ddc49cc754740e90b438$$aDill, Michael$$b15$$eLast author$$udkfz
000288743 773__ $$0PERI:(DE-600)2222136-0$$a10.1007/s11523-024-01044-1$$n2$$p213-221$$tTargeted oncology$$v19$$x1776-2596$$y2024
000288743 8564_ $$uhttps://inrepo02.dkfz.de/record/288743/files/s11523-024-01044-1.pdf
000288743 8564_ $$uhttps://inrepo02.dkfz.de/record/288743/files/s11523-024-01044-1.pdf?subformat=pdfa$$xpdfa
000288743 909CO $$ooai:inrepo02.dkfz.de:288743$$pVDB
000288743 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000288743 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)54a6641a6c26ddc49cc754740e90b438$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000288743 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000288743 9141_ $$y2024
000288743 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-25$$wger
000288743 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-25$$wger
000288743 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000288743 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000288743 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000288743 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-25
000288743 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000288743 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000288743 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-25
000288743 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000288743 9202_ $$0I:(DE-He78)F240-20160331$$kF240$$lNWG Experimentelle Hepatologie, Entzündung und Krebs$$x0
000288743 9201_ $$0I:(DE-He78)F240-20160331$$kF240$$lNWG Experimentelle Hepatologie, Entzündung und Krebs$$x0
000288743 9201_ $$0I:(DE-He78)D500-20160331$$kD500$$lNWG Experimentelle Hepatologie, Entzündung und Krebs$$x1
000288743 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lD120 Angewandte Tumor-Immunität$$x2
000288743 980__ $$ajournal
000288743 980__ $$aVDB
000288743 980__ $$aI:(DE-He78)F240-20160331
000288743 980__ $$aI:(DE-He78)D500-20160331
000288743 980__ $$aI:(DE-He78)D120-20160331
000288743 980__ $$aUNRESTRICTED